Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Vaccine ; 26(52): 6759-67, 2008 Dec 09.
Artigo em Inglês | MEDLINE | ID: mdl-18950671

RESUMO

First generation candidate vaccines against leishmaniasis, prepared using inactivated whole parasites as their main ingredient, were considered as promising because of their relative ease of production and low cost. These vaccines have been the subject of many investigations over several decades and are the only leishmaniasis vaccine candidates which have undergone phase 3 clinical trial evaluation. Although the studies demonstrated the safety of the vaccines and several studies showed reasonable immunogenicity and some indication of protection, an efficacious prophylactic vaccine is yet to be identified. Despite this overall failure, these trials contributed significantly to increasing knowledge on human leishmaniasis immunology. To provide a collective view, this review discusses the methods and findings of field efficacy trials of first generation leishmaniasis vaccine clinical trials conducted in the Old and New Worlds.


Assuntos
Vacinas contra Leishmaniose/uso terapêutico , Leishmaniose/imunologia , Leishmaniose/prevenção & controle , África/epidemiologia , Animais , Ásia/epidemiologia , Ensaios Clínicos como Assunto , Humanos , Leishmania/imunologia , Ensaios Clínicos Controlados Aleatórios como Assunto , América do Sul/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA